[{"orgOrder":0,"company":"PharmaMar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaMar has submitted a Phase II clinical trial of Aplidin for the treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SPAIN","productType":"Peptide","productStatus":"Approved","date":"April 2020","url1":"","url2":"","graph1":"Peptide","graph2":"PharmaMar"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaMar Gets Spanish Medicines Agency Authorization for APLICOV-PC Clinical Trial With Aplidin\u00ae for the Treatment of COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SPAIN","productType":"Peptide","productStatus":"Approved","date":"April 2020","url1":"","url2":"","graph1":"Peptide","graph2":"PharmaMar"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORYZON to Initiate ESCAPE, Phase II Clinical Trial to Test Efficacy of Vafidemstat in Severely Ill COVID-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SPAIN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Oryzon Genomics"},{"orgOrder":0,"company":"Laboratorios HIPRA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AEMPS Authorizes Phase IIb Clinical Trial of HIPRA Covid-19 Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SPAIN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Laboratorios HIPRA"},{"orgOrder":0,"company":"Laboratorios HIPRA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AEMPS Authorizes Phase III Clinical Trial of the Hipra\u2019s Vaccine Against Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SPAIN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Laboratorios HIPRA"},{"orgOrder":0,"company":"Aelix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AELIX Has Presented Positive Results from the Clinical Study AELIX-002 at the 2021 Conference on Retroviruses and Opportunistic Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SPAIN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Aelix Therapeutics"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Messenger RNA based Covid Vaccine is an adjuvanted recombinant protein vaccine based on a receptor-binding domain (RBD) fusion heterodimer containing variants alpha and beta of SARS-CoV-2 is authorized for phase III clinical trial.
Lead Product(s):
Adjuvanted Recombinant Protein Vaccine
The main objectives of the Phase IIb trial are to confirm safety and tolerability for a booster dose and to check if the booster dose prolongs the immune response to Covid-19 in people who have already been vaccinated.
Lead Product(s):
Messenger RNA Based Covid Vaccine
HTI-based vaccines as a component of combination cure regimens are being evaluated in the ongoing AELIX-003 clinical trial testing HTI in combination with Gilead’s investigational TLR7 agonist vesatolimod, in people living with HIV on ART.